NO2012016I2 - Kombinasjon av HPV16 og HPV18 L1 viruslignende partikler - Google Patents

Kombinasjon av HPV16 og HPV18 L1 viruslignende partikler

Info

Publication number
NO2012016I2
NO2012016I2 NO2012016C NO2012016C NO2012016I2 NO 2012016 I2 NO2012016 I2 NO 2012016I2 NO 2012016 C NO2012016 C NO 2012016C NO 2012016 C NO2012016 C NO 2012016C NO 2012016 I2 NO2012016 I2 NO 2012016I2
Authority
NO
Norway
Prior art keywords
hpv18
hpv16
virus
particles
combination
Prior art date
Application number
NO2012016C
Other languages
English (en)
Other versions
NO2012016I1 (no
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of NO2012016I2 publication Critical patent/NO2012016I2/no
Publication of NO2012016I1 publication Critical patent/NO2012016I1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
    • B09C—RECLAMATION OF CONTAMINATED SOIL
    • B09C1/00—Reclamation of contaminated soil
    • E—FIXED CONSTRUCTIONS
    • E02—HYDRAULIC ENGINEERING; FOUNDATIONS; SOIL SHIFTING
    • E02D—FOUNDATIONS; EXCAVATIONS; EMBANKMENTS; UNDERGROUND OR UNDERWATER STRUCTURES
    • E02D3/00—Improving or preserving soil or rock, e.g. preserving permafrost soil
    • E02D3/11—Improving or preserving soil or rock, e.g. preserving permafrost soil by thermal, electrical or electro-chemical means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Environmental & Geological Engineering (AREA)
  • Soil Sciences (AREA)
  • Structural Engineering (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Paleontology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Agronomy & Crop Science (AREA)
  • Biotechnology (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Mining & Mineral Resources (AREA)
  • Biochemistry (AREA)
  • Civil Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
NO2012016C 1999-09-07 2012-10-08 Kombinasjon av HPV16 og HPV18 L1 viruslignende partikler NO2012016I1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9921146A GB9921146D0 (en) 1999-09-07 1999-09-07 Novel composition
PCT/EP2000/008784 WO2001017551A2 (en) 1999-09-07 2000-09-07 Combined vaccine compositions

Publications (2)

Publication Number Publication Date
NO2012016I2 true NO2012016I2 (no) 2012-10-08
NO2012016I1 NO2012016I1 (no) 2012-10-15

Family

ID=10860520

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20021116A NO332800B1 (no) 1999-09-07 2002-03-06 Vaksinesammensetning egnet for behandling eller profylakse av humanpapillomavirusinfeksjoner og herpes simpleksvirusinfeksjoner
NO20033715A NO331825B1 (no) 1999-09-07 2003-08-21 HPV viruslignende partikkel samt vaksine
NO2012016C NO2012016I1 (no) 1999-09-07 2012-10-08 Kombinasjon av HPV16 og HPV18 L1 viruslignende partikler

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NO20021116A NO332800B1 (no) 1999-09-07 2002-03-06 Vaksinesammensetning egnet for behandling eller profylakse av humanpapillomavirusinfeksjoner og herpes simpleksvirusinfeksjoner
NO20033715A NO331825B1 (no) 1999-09-07 2003-08-21 HPV viruslignende partikkel samt vaksine

Country Status (33)

Country Link
US (3) US6936255B1 (no)
EP (3) EP1210113B1 (no)
JP (2) JP4689910B2 (no)
KR (2) KR100557665B1 (no)
CN (2) CN100389824C (no)
AR (1) AR025502A1 (no)
AT (2) ATE321569T1 (no)
AU (1) AU766494B2 (no)
BR (1) BR0014171A (no)
CA (2) CA2443214C (no)
CO (1) CO5280045A1 (no)
CY (2) CY1107457T1 (no)
CZ (2) CZ302811B6 (no)
DE (2) DE60024893T2 (no)
DK (2) DK1410805T3 (no)
ES (2) ES2253636T3 (no)
GB (1) GB9921146D0 (no)
GC (1) GC0000201A (no)
HK (1) HK1048435B (no)
HU (2) HU229099B1 (no)
IL (3) IL158107A0 (no)
MX (1) MXPA02002484A (no)
MY (2) MY130084A (no)
NO (3) NO332800B1 (no)
NZ (2) NZ527560A (no)
PL (2) PL201264B1 (no)
PT (1) PT1210113E (no)
SG (1) SG110072A1 (no)
SI (2) SI1210113T1 (no)
TR (1) TR200200607T2 (no)
TW (1) TWI258374B (no)
WO (1) WO2001017551A2 (no)
ZA (2) ZA200306402B (no)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20060029617A1 (en) * 1997-10-03 2006-02-09 Charreyre Catherine E Porcine circovirus and Helicobacter combination vaccines and methods of use
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
IL139813A0 (en) 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
DE122007000087I1 (de) * 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
ATE354662T1 (de) 2001-03-23 2007-03-15 Deutsches Krebsforsch Modifizierte hpv e6- und e7-gene und -proteine als impfstoff
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7407807B2 (en) † 2002-05-17 2008-08-05 University Of Cape Town Chimaeric human papillomavirus 16 I1 virus like particles and a method for preparing the particles
WO2004011650A2 (en) 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
WO2004024182A2 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
CN1753687A (zh) 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
ATE503492T1 (de) * 2002-12-20 2011-04-15 Glaxosmithkline Biolog Sa Verwendung von hpv16 und hpv18 vlps als vakzine gegen eine oder mehrere onkogene hpv des typus 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
SI1572233T1 (sl) * 2002-12-20 2011-07-29 Glaxosmithkline Biolog Sa Uporaba HPV16 in HPV18 kot cepivo proti enemu ali več onkogenih HPV tipa 31,33,35,39,45,51,52,56,58,59,66,68
US7704514B2 (en) 2003-03-24 2010-04-27 Intercell Ag Vaccines
CN101214375B (zh) * 2003-03-24 2011-04-06 英特塞尔股份公司 改进的疫苗
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
GB0413510D0 (en) * 2004-06-16 2004-07-21 Glaxosmithkline Biolog Sa Vaccine
MXPA06014515A (es) * 2004-06-16 2007-03-23 Glaxosmithkline Biolog Sa Vacuna contra vph16 y vph18 y al menos otro tipo de vph seleccionado de vph 31, 45 o 52.
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
JP2008530195A (ja) * 2005-02-16 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド リン酸アルミニウムおよび３ｄ−ｍｐｌを含むアジュバント組成物
JP4182074B2 (ja) 2005-03-03 2008-11-19 ファナック株式会社 ハンド及びハンドリングロボット
TW200700079A (en) * 2005-03-23 2007-01-01 Glaxosmithkline Biolog Sa Composition
KR20080005583A (ko) * 2005-04-26 2008-01-14 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
KR20080005585A (ko) * 2005-04-26 2008-01-14 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
US7790203B2 (en) * 2005-12-13 2010-09-07 Lowder Tom R Composition and regimen for the treatment of herpes simplex virus, herpes zoster, and herpes genitalia epidermal herpetic lesions
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US20080226669A1 (en) 2005-12-29 2008-09-18 Boehringer Ingelheim Vetmedica, Inc. Multivalent pcv2 immunogenic compositions and methods of producing such compositions
PL2371383T3 (pl) 2005-12-29 2016-01-29 Boehringer Ingelheim Vetmedica Inc Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń
WO2008027394A2 (en) 2006-08-28 2008-03-06 The Wistar Institute Of Anatomy And Biology Constructs for enhancing immune responses
HUE036180T2 (hu) 2006-09-26 2018-06-28 Infectious Disease Res Inst Szintetikus adjuvánst tartalmazó vakcina készítmény
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
EP2129394B1 (en) 2007-03-09 2012-06-20 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
CN101835796A (zh) 2007-06-26 2010-09-15 财团法人日本健康科学振兴财团 诱导抗高危型人乳头瘤病毒的交叉反应性中和抗体的疫苗抗原
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
CN102112153B (zh) 2008-06-04 2014-04-16 一般财团法人化学及血清疗法研究所 灭活日本脑炎病毒颗粒作为佐剂的用途
SI2318042T1 (sl) * 2008-07-31 2014-12-31 Glaxosmithkline Biologicals S.A. Cepivo proti HPV
AU2010249330B2 (en) 2009-05-22 2015-11-05 Genocea Biosciences Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
HUE031051T2 (en) 2009-06-05 2017-06-28 Infectious Disease Res Inst Synthetic glycopyranosyl lipid adjuvant and vaccine compositions containing it
WO2010147268A1 (ko) 2009-06-19 2010-12-23 아이진 주식회사 자궁경부암 백신
MX2011013744A (es) * 2009-06-25 2012-09-28 Glaxosmithkline Biolog Sa Construcciones novedosas de proteinas del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv.
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
BR112012030337B1 (pt) * 2010-05-28 2021-04-27 Coley Pharmaceutical Group, Inc Vacina compreendendo um ou mais oligonucleotídeo(s) de cpg isolado(s) ou um agonista de tlr e colesterol, e uso da mesma
UA112970C2 (uk) * 2010-08-05 2016-11-25 Мерк Шарп Енд Доме Корп. Інактивований вірус вітряної віспи, спосіб його одержання і застосування
CN103154737B (zh) * 2010-08-27 2015-07-15 英特维特国际股份有限公司 疫苗制剂的效价测试
CN102008721A (zh) * 2010-11-16 2011-04-13 浙江大学 一种hpv多肽/dc混合疫苗及其制备
AU2011336894B2 (en) 2010-11-24 2016-11-17 Genocea Biosciences, Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
EP3632463A1 (en) 2011-04-08 2020-04-08 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN102210858B (zh) * 2011-05-18 2013-05-08 北京科兴生物制品有限公司 一种肠道病毒71型与甲型肝炎联合疫苗
AU2012272788B2 (en) * 2011-06-24 2016-10-20 Merck Sharp & Dohme Llc HPV vaccine formulations comprising aluminum adjuvant and methods of producing same
AU2012279154A1 (en) * 2011-07-01 2014-02-20 The Regents Of The University Of California Herpes virus vaccine and methods of use
AU2012340712B2 (en) 2011-11-23 2017-09-14 Genocea Biosciences, Inc. Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
WO2013119856A1 (en) 2012-02-07 2013-08-15 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccines for hsv-2
US9624510B2 (en) 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
EP2986303B1 (en) 2013-04-18 2020-02-26 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL246456B2 (en) 2013-12-31 2024-06-01 Access To Advanced Health Inst Formulations will be assembled into a single vial
EP3490610A4 (en) 2016-08-01 2020-05-20 The Wistar Institute Of Anatomy And Biology Compositions and methods of replication deficient adenoviral vectors for vaccine applications
JP2019537555A (ja) 2016-09-28 2019-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド ヘルペスを処置するための方法および組成物
CN107987159B (zh) * 2017-11-28 2021-06-22 上海药明生物医药有限公司 一种使用大剂量dna免疫技术免疫动物使血清中抗体滴度提高的方法
GB201821207D0 (en) 2018-12-24 2019-02-06 Tcer Ab Immunotherapy therapy
WO2020243115A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
CN110576034B (zh) * 2019-10-09 2020-06-30 北京尚华生态环保科技股份公司 一种土壤原位修复方法
CN110652980B (zh) * 2019-10-09 2020-06-30 北京尚华生态环保科技股份公司 一种土壤原位修复剂
US20220396797A1 (en) 2019-11-15 2022-12-15 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
CN114681602B (zh) * 2020-12-25 2023-12-01 中国食品药品检定研究院 一种双价人乳头瘤病毒疫苗
CN114796479B (zh) * 2022-06-02 2026-02-10 金宇保灵生物药品有限公司 一种畜类动物疫苗用水包油包水佐剂及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH085804B2 (ja) * 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
DE122007000085I1 (de) * 1991-07-19 2008-03-27 Univ Queensland St Lucia Polynukleotidabschnitt des HPV16-Genoms
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
EP0689454B2 (en) 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9409962D0 (en) * 1994-05-18 1994-07-06 Smithkline Beecham Biolog Novel compounds
AU4727296A (en) * 1995-02-24 1996-09-11 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US6172192B1 (en) * 1996-01-26 2001-01-09 Innogenetics N.V. Toxoplasma gondii antigen Tg20
ES2301175T3 (es) * 1996-02-09 2008-06-16 Smithkline Beecham Biologicals S.A. Vacunas contra el producto del gen 63 del virus de la varicela zoster.
GB9711990D0 (en) * 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
CA2229955C (en) * 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
ES2273482T3 (es) * 1998-03-09 2007-05-01 Glaxosmithkline Biologicals S.A. Composiciones de vacunas combinadas.
US6500284B1 (en) 1998-06-10 2002-12-31 Suraltech, Inc. Processes for continuously producing fine grained metal compositions and for semi-solid forming of shaped articles
GB9819898D0 (en) 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
DE122007000087I1 (de) 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
SI1150712T1 (sl) * 1999-02-05 2009-02-28 Merck & Co Inc Pripravek cepiva proti humanem papiloma virusu
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition

Also Published As

Publication number Publication date
US6936255B1 (en) 2005-08-30
CZ302811B6 (cs) 2011-11-23
ATE321569T1 (de) 2006-04-15
AU766494B2 (en) 2003-10-16
CZ2002843A3 (cs) 2002-08-14
DE60027029D1 (de) 2006-05-18
KR20030087081A (ko) 2003-11-12
JP2003508495A (ja) 2003-03-04
ZA200201810B (en) 2004-05-26
CA2443214C (en) 2006-03-21
TW200408405A (en) 2004-06-01
SI1410805T1 (sl) 2006-04-30
NO20033715L (no) 2002-04-30
ZA200306402B (en) 2004-08-02
ATE312624T1 (de) 2005-12-15
CA2443214A1 (en) 2001-03-15
SG110072A1 (en) 2005-04-28
EP1769806A2 (en) 2007-04-04
IL158107A (en) 2008-11-03
CN1387443A (zh) 2002-12-25
NO20021116L (no) 2002-04-30
HUP0202804A2 (hu) 2002-12-28
JP2004067696A (ja) 2004-03-04
KR100557665B1 (ko) 2006-03-06
TWI258374B (en) 2006-07-21
NZ527560A (en) 2004-12-24
KR100594668B1 (ko) 2006-06-30
DE60024893D1 (de) 2006-01-19
DE60024893T2 (de) 2006-07-06
IL158107A0 (en) 2004-03-28
KR20020027630A (ko) 2002-04-13
US7220551B2 (en) 2007-05-22
CN1618465A (zh) 2005-05-25
CA2384064C (en) 2010-06-01
EP1410805A1 (en) 2004-04-21
NO2012016I1 (no) 2012-10-15
US20040126394A1 (en) 2004-07-01
JP4689910B2 (ja) 2011-06-01
US7101560B2 (en) 2006-09-05
EP1210113B1 (en) 2006-03-29
AR025502A1 (es) 2002-11-27
WO2001017551A2 (en) 2001-03-15
SI1210113T1 (sl) 2006-08-31
HU229099B1 (en) 2013-07-29
TR200200607T2 (tr) 2002-06-21
ES2261243T3 (es) 2006-11-16
NZ517621A (en) 2003-09-26
PL354039A1 (en) 2003-12-15
HK1064958A1 (en) 2005-02-08
CY1107457T1 (el) 2012-12-19
CO5280045A1 (es) 2003-05-30
WO2001017551A3 (en) 2001-09-27
HU0303215D0 (en) 2003-11-28
HUP0202804A3 (en) 2004-08-30
MXPA02002484A (es) 2002-08-28
MY142842A (en) 2011-01-14
CN100389824C (zh) 2008-05-28
AU7775100A (en) 2001-04-10
CY1106090T1 (el) 2011-06-08
BR0014171A (pt) 2002-05-21
NO20033715D0 (no) 2003-08-21
CA2384064A1 (en) 2001-03-15
MY130084A (en) 2007-05-31
NO20021116D0 (no) 2002-03-06
HUP0303215A3 (en) 2008-04-28
HK1048435A1 (en) 2003-04-04
EP1769806A3 (en) 2007-10-24
HK1048435B (en) 2007-01-05
EP1210113A2 (en) 2002-06-05
DE60027029T2 (de) 2006-10-19
NO332800B1 (no) 2013-01-14
GC0000201A (en) 2006-03-29
PL201767B1 (pl) 2009-05-29
HU228687B1 (en) 2013-05-28
NO331825B1 (no) 2012-04-10
PT1210113E (pt) 2006-07-31
GB9921146D0 (en) 1999-11-10
EP1410805B1 (en) 2005-12-14
US20060280756A1 (en) 2006-12-14
ES2253636T3 (es) 2006-06-01
DK1210113T3 (da) 2006-07-03
PL201264B1 (pl) 2009-03-31
CN1325117C (zh) 2007-07-11
IL148456A0 (en) 2002-09-12
DK1410805T3 (da) 2006-04-18

Similar Documents

Publication Publication Date Title
NO2012016I1 (no) Kombinasjon av HPV16 og HPV18 L1 viruslignende partikler
AP2004003136A0 (en) Virus-like particles of human papillomavirus
AU2003227533A1 (en) Virus like particle from papillomavirus and their use in vaccine
HUP0004360A2 (en) Papilloma virus capsomere vaccine formulations and methods of use
DE60040727D1 (de) Menschliche papillomavirus impfstoff-formulierungen
AU2002330943A1 (en) Immunomodulatory compounds and methods of use thereof
EP1524974A4 (en) TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE
DE60040879D1 (de) Impfstoff gegen Hbv und Hpv
AU2003235707A1 (en) Immunogenic preparations and vaccines on the basis of mrna
AU2002335085A1 (en) Angiopoietins and methods of use thereof
TWI349557B (en) Use of hpv 16 and hpv 18 vlps for vaccine preparation
NO20015542D0 (no) Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner
AU2002306991A1 (en) Detection and amplification of ligands
AU2001296864A1 (en) Detection of varicella-zoster virus
AU2002220744A1 (en) T-cell epitope of the papillomavirus L1 and E7 protein and use thereof in diagnostics and therapy
AU2003290012A1 (en) L2-peptide of the human papillomavirus associated with virus-like particles
AU2001247196A1 (en) Methods and compositions for detection of disease
AU2001270908A1 (en) Methods for detection of human papillomavirus mrna
AU5825801A (en) Method and device for the direct drying of particles
AU8582701A (en) Use of strains of the parapox ovis virus against organ fibrosis
AU2001285827A1 (en) Use of strains of the parapox ovis virus against organ fibrosis
AU2001285827A2 (en) Use of strains of the parapox ovis virus against organ fibrosis
AU2003287216A1 (en) Gb virus c and methods of treating viral infections
HUP0303418A3 (en) Inhibitors of papilloma virus
AU2001270209A1 (en) Hiv-1 vaccines and screening methods therefor